Skip to main content
IART logo

Integra LifeSciences Holdings Corporation (IART) Stock Price & Analysis

Integra LifeSciences Holdings Corporation (IART) — MoonshotScore 68/100 (Strong band), calculated Nov 18, 2026. Price $13.25 (-2.21%), as of the Nov 20, 2026 trading session; market cap $1.03B.

Educational signal · not a buy or sell recommendation · How to read this

$13.25 −$0.30 (-2.21%) Market Cap $1.03B

Integra LifeSciences Holdings Corporation · IART · NASDAQ

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments. The company operates through Codman Specialty Surgical and Tissue Technologies segments, providing solutions for neurosurgery, extremity reconstruction, and general surgery.

Price as of Nov 20, 2026

Key Statistics

68 of 100

MoonshotScore v2 · Integra LifeSciences Holdings (IART)

Strong
Business Quality Elite (81)
Financial Safety Strained (29)
Valuation Fair (78)
Growth Durability Compounding (86)
Momentum Rising (66)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and durable growth, but a strained balance sheet. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.

  • EPS beat 0 of the last 4 reports
  • Altman Z 1.31 · Piotroski F 7
  • ROE 1.2% · ROA 2.9% · current ratio 3.62

Holding back: balance-sheet strain

Helping: business quality, an attractive price, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for IART (58 recorded, newest six shown)
RecordedScoreBand
66Strong
62Fair
62Fair
68Strong
68Strong
68Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$13.25
Change on the day-2.21%
52-week range$8.70 – $20.49
Market capitalisation$1.03B—
Price / earnings (trailing)80.75
Shares traded on the day826.6K

Price & events

Other perspectives

Council score for Integra LifeSciences Holdings (IART): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Weak
Valuation Moderate
Growth Durability Strong
Momentum Moderate

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Debt/Equity Negative
ROE Weak
Gross Margin Moderate

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Integra LifeSciences Holdings (IART), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Integra LifeSciences Holdings Corporation (IART) is listed on NASDAQ. It employs 4,427 people and is led by Stuart Essig. The market values it at $1.03B.

2 · Latest results

What do the latest results show for Integra LifeSciences Holdings (IART)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$402M-$5M-$0.07 (diluted)
Q4 FY2025$435M-$2M-$0.02 (diluted)
Q1 FY2026$392M-$5M-$0.06 (diluted)
Q2 FY2026$419M$4M$0.06 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Integra LifeSciences Holdings (IART)?

Short answer

The MoonshotScore pillars rate business quality, an attractive price, durable growth as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 1.31 · Piotroski F 7. Trailing ratios: ROE 1.2% · ROA 2.9% · current ratio 3.62.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.31 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Integra LifeSciences Holdings (IART)?

Short answer · as of

The stored analyst-target capture is expired, so a current target watchpoint is unavailable.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Integra LifeSciences Holdings compare with its peers?

Short answer

Integra LifeSciences Holdings's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
IRadimed Corporation (IRMD) Same industry, near in market value$81.02 Nov 20, 2026$1.04B94 5-pillar Nov 18, 2026
InMode Ltd. (INMD) Same industry, near in market value$12.42 Nov 20, 2026$715M92 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Named competitor$270.47 Nov 20, 2026$651B83 5-pillar Nov 18, 2026
Medtronic plc (MDT) Named competitor$99.94 Nov 20, 2026$128B81 5-pillar Nov 18, 2026
CONMED Corporation (CNMD) Same industry, near in market value$46.56 Nov 20, 2026$1.39B79 5-pillar Nov 18, 2026
Bioventus Inc. (BVS) Same industry, near in market value$9.95 Nov 19, 2026$681M79 5-pillar Nov 18, 2026
Boston Scientific Corporation (BSX) Named competitor$41.98 Nov 20, 2026$60.9B77 5-pillar Nov 18, 2026
Integra LifeSciences Holdings (IART) — this page$13.25$1.03B68
Varex Imaging Corporation (VREX) Same industry, near in market value$18.10 Nov 20, 2026$769M62 5-pillar Nov 18, 2026
SI-BONE, Inc. (SIBN) Same industry, near in market value$23.73 Nov 20, 2026$1.07B39 5-pillar Nov 18, 2026
OrthoPediatrics Corp. (KIDS) Same industry, near in market value$31.74 Nov 20, 2026$829M37 5-pillar Nov 18, 2026
Artivion Inc. (AORT) Same industry, near in market value$18.16 Nov 20, 2026$886M34 5-pillar Nov 18, 2026
Cytek Biosciences, Inc. (CTKB) Same industry, near in market value$6.12 Nov 20, 2026$800M33 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
$13.00 – $25.00
Last captured analyst target (expired, captured Nov 18, 2026)
$16.43
Last captured median analyst target (expired, captured Nov 18, 2026)
$14.00

Historical target record · Captured · Capture expired; not a current watchpoint.

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 1, 2026

Transactions
5
Identified insiders
5
Purchases
0
Sales
0
Other transactions
5

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IART in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported IART in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Integra LifeSciences Holdings (IART)?

Read these with our analysis →

Common Questions About IART

These answers are editorial: 1 of these 9 answers is drawn from the IART research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for IART?

IART carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments.

Is IART a good stock to buy?

Stock Expert AI does not rate IART buy, sell or hold. Integra LifeSciences Holdings Corporation carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the IART stock price today?

The last price recorded for Integra LifeSciences Holdings Corporation (IART), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the IART price target?

The last analyst consensus price target we captured for Integra LifeSciences Holdings Corporation (IART), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

What do analysts say about IART stock?

Analyst coverage of Integra LifeSciences is mixed, reflecting the company's challenges and opportunities. Some analysts highlight the company's strong market position in neurosurgery and tissue technologies, while others express concerns about its negative profit margin and high debt levels.

What are the key factors to evaluate for IART?

Integra LifeSciences Holdings Corporation (IART) holds a MoonshotScore in the moderate range. To weigh it, start with the trailing P/E under Price & valuation on this page. Global presence across the United States, Europe, and Asia Pacific provides access to multiple markets. Not financial advice.

How frequently does IART data refresh on this page?

IART's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven IART's recent stock price performance?

Integra LifeSciences Holdings Corporation (IART) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in neurosurgery and tissue technologies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider IART overvalued or undervalued right now?

The trailing P/E of Integra LifeSciences Holdings Corporation (IART) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.